PMC:7558233 / 33780-34197
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
860 | 78-86 | Species | denotes | patients | Tax:9606 |
861 | 284-292 | Species | denotes | patients | Tax:9606 |
866 | 155-168 | Chemical | denotes | dexamethasone | MESH:D003907 |
867 | 365-371 | Chemical | denotes | oxygen | MESH:D010100 |
875 | 92-100 | Disease | denotes | COVID-19 | MESH:C000657245 |
876 | 231-240 | Disease | denotes | mortality | MESH:D003643 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T201 | 0-417 | Sentence | denotes | In an echo of these findings, a recent clinical trial recruiting hospitalized patients with COVID-19 showed that the oral or intravenous administration of dexamethasone (6 mg·d–1) for up to 10 d resulted in a markedly lower 28-day mortality in comparison with the control group among patients receiving invasive mechanical ventilation at randomization or receiving oxygen without invasive mechanical ventilation [93]. |